Piper Sandler Reaffirms Their Buy Rating on Teladoc (TDOC)

In a report released today, Jessica Tassan from Piper Sandler reiterated a Buy rating on Teladoc (TDOC – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $14.62.

Tassan covers the Healthcare sector, focusing on stocks such as CVS Health, Teladoc, and Health Catalyst. According to TipRanks, Tassan has an average return of -0.4% and a 43.00% success rate on recommended stocks.

In addition to Piper Sandler, Teladoc also received a Buy from Barclays’s Stephanie Davis in a report issued yesterday. However, on April 5, Deutsche Bank maintained a Hold rating on Teladoc (NYSE: TDOC).

Based on Teladoc’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $660.24 million and a GAAP net loss of $57.07 million. In comparison, last year the company earned a revenue of $611.4 million and had a GAAP net loss of $73.48 million

Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TDOC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teladoc (TDOC) Company Description:

Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company. The company provides telehealth solutions, expert medical services, medical opinions, artificial intelligence and analytics, behavioral health solutions, guidance and support, and platform and program services.